Amputation Risk in Type II Diabetes Mellitus Patients Treated with SGLT-2 Inhibitors: A Systematic Literature Review of Randomized Clinical Trials
Amputationsrisiko bei Patient:innen mit Typ-2-Diabetes unter SGLT-2-Inhibitoren: systematische Literaturübersicht randomisierter klinischer Studien
Drug Research · 01.11.2024 · 74 (09) · 425-432
DOI: 10.1055/a-2366-8999 ↗Auf einen Blick
Die Übersicht von 12 RCTs fand insgesamt keinen signifikanten Unterschied bei Amputationen zwischen SGLT-2-Inhibitoren und Placebo. Für Canagliflozin wurden in einzelnen Studien mehr Amputationen berichtet.
Fragestellung
Erhöhen SGLT-2-Inhibitoren bei Patient:innen mit Typ-2-Diabetes das Amputationsrisiko im Vergleich zu Placebo?
Methode
Systematische Literaturübersicht nach PRISMA; Suche in elektronischen Datenbanken von Beginn bis Mai 2024; Qualitätsbewertung mit dem Cochrane ROB-Tool.
Ergebnisse
12 RCTs; 37.657 Teilnehmende mit SGLT-2-Inhibitoren und 30.959 mit Placebo. 618 Ereignisse in der Behandlungsgruppe und 396 in der Placebogruppe; kein signifikanter Unterschied insgesamt.
Schlussfolgerung der Autor:innen
Patient:innen unter SGLT-2-Inhibitoren zeigten insgesamt keinen signifikanten Unterschied bei Amputationen gegenüber Placebo; Canagliflozin war in einzelnen Studien mit mehr Amputationen verbunden.
Kernaussagen
- 12 RCTs wurden in die Übersicht eingeschlossen.
- Insgesamt kein signifikanter Unterschied bei Amputationen vs. Placebo.
- Canagliflozin zeigte in einzelnen Studien mehr Amputationen.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Drug Research, erschienen am 01.11.2024. Verfasst von Farazul Hoda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Amputation, Surgical, Randomized Controlled Trials as Topic. Die Arbeit nennt 45 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
SGLT-2 inhibitors, prescribed for type 2 diabetes, have a heightened risk of amputation. The FDA issued a warning in May 2017, leading to the inclusion of a cautionary label. Vigilance is essential for patients and healthcare providers to promptly identify and address potential limb complications associated with the use of SGLT-2 inhibitors.
Method
A comprehensive search of electronic databases was conducted, covering the period from inception to May 2024. This systematic literature review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The quality of the included studies was assessed using the Cochrane risk of bias (ROB) tool. Inclusion and exclusion criteria were predefined, and data extraction was performed to summarize the findings.
Result
A total of 12 randomized control trial (RCT) studies were included in the present systematic review. 37,657 (54.89%) participants were randomly assigned to receive the different interventions of SGLT-2 inhibitor, whereas 30,959 (45.11%) received a placebo. Overall, 618 events were reported in the treatment group, whereas 396 events were reported in the placebo group.
Conclusion
In conclusion, patients treated with SGLT-2 inhibitors did not have any significant difference in amputation occurrences compared to placebo across various studies. However, canagliflozin usage has led to higher amputation events in certain trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Faculty of Medical and Health Sciences, Liwa College, Al Ain, Abu Dhabi, United Arab Emirates.
- Department of Pharmacology, Integral University, Lucknow, U.P., India.
- Department of Medicine, Hamdard Institute of Medical Sciences & Research, Jamia Hamdard, New Delhi, India.
Zitieren
APA
Hoda, F., Jamali, M. C., Arshad, M., Habib, M. A., Akhtar, M., & Najmi, A. K. (2024). Amputation Risk in Type II Diabetes Mellitus Patients Treated with SGLT-2 Inhibitors: A Systematic Literature Review of Randomized Clinical Trials. Drug Research, 74(09), 425-432. https://doi.org/10.1055/a-2366-8999
Vancouver
Hoda F, Jamali MC, Arshad M, Habib MA, Akhtar M, Najmi AK. Amputation Risk in Type II Diabetes Mellitus Patients Treated with SGLT-2 Inhibitors: A Systematic Literature Review of Randomized Clinical Trials. Drug Research. 2024;74(09):425-432. doi:10.1055/a-2366-8999
BibTeX
@article{Hoda2024,
author = {Hoda, Farazul and Jamali, Mohammad Chand and Arshad, Mawrah and Habib, Mohammad Anwar and Akhtar, Mohd and Najmi, Abul Kalam},
title = {Amputation Risk in Type II Diabetes Mellitus Patients Treated with SGLT-2 Inhibitors: A Systematic Literature Review of Randomized Clinical Trials},
journal = {Drug Research},
year = {2024},
volume = {74},
number = {09},
pages = {425--432},
doi = {10.1055/a-2366-8999}
}
EUVIMED